NIAID Launches Study of Third COVID-19 Vaccine Dose in Kidney Transplant Recipients

National Institute of Allergy and Infectious Diseases sent this bulletin at 08/10/2021 10:29 AM EDT

Tuesday, August 10, 2021

NIAID Launches Study of Third COVID-19 Vaccine Dose in Kidney Transplant Recipients

Health care professional administering a vaccine

A NIAID pilot study has begun to assess the antibody response to a third dose of an authorized COVID-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech COVID-19 vaccine. The Phase 2 trial is called COVID Protection After Transplant (CPAT). The pilot study findings will inform a subsequent, larger phase of the trial that includes higher-risk strategies to induce a protective immune response against SARS-CoV-2 in solid organ transplant recipients who do not respond to a third dose of an mRNA vaccine. People who would like to enroll in the CPAT pilot study, which is taking place at Johns Hopkins University in Baltimore, should email dose3@jhu.edu.

National Institute of Allergy and Infectious Diseases | National Institutes of Health

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help.

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).